March 30, 2017 — New late-breaking featured clinical research presented today adds strong clinical support for Abbott's CardioMEMS HF System as an effective real-world approach to reduce heart failure hospitalizations and combat the rising cost of heart failure. The CardioMEMS HF System is the first U.S. Food and Drug Administration-approved monitor that has been shown to significantly reduce heart failure hospital admissions and improve the quality of life in patients with heart failure (NYHA Class III).

The Connecticut Hospital Association (CHA) and Bayer announced an alliance to establish the United States' first-ever statewide radiation dose management repository for patients undergoing certain radiological procedures. The repository will use Bayer’s Radimetrics, a radiation and contrast dose management and analytics tool which provides clinicians with data needed for them to help ensure their patients receive the lowest radiation dosage necessary. The goal is for clinicians to be able to share the data in order to benchmark radiation exposure.

Automated external defibrillators (AEDs) are associated with increased survival of sudden cardiac arrest when installed in schools, yet only 17 out of 50 U.S. states require AED installation in at least some of their schools, according to a new analysis. The analysis was published in the Journal of the American College of Cardiology.

Acarix AB recently announced the results from a new multi-center trial of its handheld CADScor System for non-invasive, non-radiation acoustic detection of coronary artery disease (CAD). The results were presented at the American College of Cardiology (ACC) 2017 Annual Scientific Meeting, held March 17-19 in Washington, D.C., and showed the handheld CADScor System rules out CAD with 97 percent negative predictive value. The results confirm the company’s previously announced figures which, prior to this study, were unconfirmed.

atricure atriclip, LAA occlusion, acc17

March 29, 2017 — For patients with atrial fibrillation (AFib), closing the area of the heart known as the left atrial appendage (LAA) as an add-on procedure during cardiac surgery was associated with a 40 percent reduction in the risk of thromboembolism according to an observational study presented at the American College of Cardiology (ACC) 2017 Annual Scientific Session.
Ablation procedure, EP lab, Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation

March 29, 2017 — Uninterrupted treatment with dabigatran (Pradaxa), a non-vitamin K, novel antagonist oral anticoagulant (NOAC), before, during and after ablation to treat atrial fibrillation significantly reduced the incidence of major bleeding events compared with uninterrupted use of the more established anticoagulant warfarin.

Injection of a novel form of synthetic high-density lipoprotein cholesterol (HDL-C), or good cholesterol, into the arteries of recent heart attack patients did not reduce the volume of plaque in the arteries compared with placebo injections, according to new research. The findings were presented at the American College of Cardiology’s 66th Annual Scientific Sessions, March 17-19 in Washington, D.C.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now